Home › Trials › NCT06006559

Assessing the effects of EYU688 on dengue fever

A Randomized, Participant- and Investigator-blinded, Placebo-controlled, Parallel Group Study to Assess the Efficacy, Safety and Pharmacokinetics of EYU688 in Patients With Dengue Fever

Phase 2 Interventional Novartis · NCT06006559

This study is testing a new treatment called EYU688 to see if it can help people with dengue fever feel better and recover faster compared to a placebo.

Quick facts

PhasePhase 2
Study typeInterventional
Enrollment108 (estimated)
Ages18 Years to 60 Years
SexAll
SponsorNovartis Industry-sponsored
Locations23 sites (Manaus, Amazonas and 22 other locations)
Trial IDNCT06006559 on ClinicalTrials.gov

What this trial studies

This study evaluates the efficacy and safety of EYU688 in treating patients with dengue fever compared to a placebo. It is a randomized, participant- and investigator-blinded, placebo-controlled trial that aims to measure the impact of EYU688 on dengue viral load, fever clearance time, and clinical symptoms. The study includes two cohorts with different pharmacokinetic sampling schedules to gather comprehensive data on the drug's effects.

Who should consider this trial

Good fit: Ideal candidates are males and females aged 18 to 60 who have a confirmed dengue infection and have experienced fever within the last 48 hours.

Not a fit: Patients with severe dengue symptoms or significant medical conditions that require other medications may not benefit from this study.

Why it matters

Potential benefit: If successful, this treatment could significantly improve recovery times and clinical outcomes for patients suffering from dengue fever.

How similar studies have performed: While there have been studies on dengue treatments, the specific approach with EYU688 is novel and has not been extensively tested in this context.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Male or female, 18 - 60 years old (inclusive).
* History or presence of fever (≥ 38°C). At least one of the following criteria indicating dengue infection:
* Nausea or vomiting.
* Presence of rash, aches or pains including headache, muscle or joint pain.
* Onset of fever ≤ 48 hours prior to treatment start.
* Positive test on dengue fever.

Exclusion Criteria:

* Participants with any of abnormalities of clinical laboratory parameters.
* Usage of any anticoagulant drugs.
* Current significant medical conditions or illness that the investigator considers should exclude the participants, especially those that require continuation of other medications likely to have an interaction with the study drug.
* Pregnant or nursing (lactating) women.
* Clinical signs and symptoms for severe dengue according to Dengue Guideline (WHO 2009) at screening.
* Participants with any of the following abnormalities of clinical laboratory parameters at screening:

  * Hemoglobin \<12.0 g/dL in males; \<11.0 g/dL in females
  * Hematocrit \>52 % in males; \>46 % in females
  * Absolute neutrophil count \<1500/μL
  * Platelet count \<80,000/mm3
  * Creatinine \>165 μmol/L in males; \>130 μmol/L in females
  * Serum creatine kinase \> 600 U/L
  * ALT, AST levels more than 1.5X upper limit of normal (ULN)
  * Total bilirubin \>24 μmol/L
* Usage of PPIs (proton pump inhibitor) which could affect absorption of EYU688 due to stomach pH value increase up to 48 hours prior to screening.
* Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during dosing and for 4 days after stopping of investigational drug.
* History or long-QT syndrome, or clinically significant ECG abnormalities, or any of the following ECG abnormalities at screening:

  * QTcF \> 450 msec (males)
  * QTcF \> 460 msec (females)

Other protocol-defined inclusion/exclusion criteria may apply.

Where this trial is running

Manaus, Amazonas and 22 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions DengueEYU688
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.